Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alefacept - Astellas Pharma

Drug Profile

Alefacept - Astellas Pharma

Alternative Names: Amevive; ASP 0485; BG 9273; BG 9712; Human LFA-3/IgG fusion protein; LFA 3 TIP; Recombinant LFA-3/IgG1 human fusion protein

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Michigan Medical School
  • Developer Astellas Pharma; Cleveland Clinic
  • Class Antipsoriatics; Recombinant fusion proteins
  • Mechanism of Action CD2 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psoriasis
  • Phase I/II Aplastic anaemia
  • Discontinued Psoriatic arthritis; Transplant rejection

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 24 Jan 2018 Astellas Pharma terminates a phase I/II trial due to the study drug not available at the time in Aplastic anaemia (Treatment-experienced) in USA (IV) (NCT01267643)
  • 15 Mar 2012 Astellas Pharma completes its Phase-II trial for Psoriasis in USA, Bulgaria and Latvia (NCT00808223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top